首页> 外文期刊>International Journal of Cardiology >Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction - A cardiovascular magnetic resonance (CMR) study
【24h】

Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction - A cardiovascular magnetic resonance (CMR) study

机译:静脉注射氧化铁对急性ST段抬高型心肌梗死患者左心室重构的积极作用-心血管磁共振(CMR)研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives This study investigated the safety profile and potential "therapeutic" effect of intravenous ultrasmall superparamagnetic iron-oxide (USPIO)-based iron administration regarding infarct healing in patients with ST-elevation myocardial infarction (STEMI). USPIO-administration was recently shown to enable an improved characterization of myocardial infarct pathology in acute STEMI patients. Materials and Methods Seventeen study patients (IRON, 54 ± 9 yrs, 88% male) and 22 matched controls (CONTROL, 57 ± 9 yrs, 77% male) both with primary reperfused STEMI underwent multi-parametric CMR studies in the first week and three months after acute MI. Only IRON patients received a single intravenous bolus of 510 mg elemental iron as ferumoxytol (FerahemeTM) within four days following acute MI. Results Three months later, all patients were alive and there were no adverse cardiac events. Significant improvement in left ventricular (LV) ejection fraction (IRON: 53 ± 10% to 59 ± 9%, p = 0.002; CONTROL: 54 ± 6% to 57 ± 10%, p = 0.005) as well as shrinkage of infarct size were seen in both groups at follow-up. There was a more pronounced decrease in infarct size in the IRON group (IRON: - 10.3 ± 5.4% vs. CONTROL: - 7.0 ± 8.4%, p = 0.050) in addition to a significant decrease in both endocardial extent and prevalence of transmural infarctions in IRON but not in CONTROL patients. A significant decrease in LV end systolic volume was only seen in the IRON group (71 ± 25 mL to 59 ± 25 mL, p = 0.002). Conclusions Intravenous iron administration in acute STEMI patients seems to be associated with an improved infarct healing and a beneficial global left ventricular remodelling. These findings together with the good safety profile make USPIO-based iron administration a promising future candidate as a "diagnostic" and "therapeutic" adjunctive solution in acute MI management.
机译:目的这项研究调查了静脉注射超小型超顺磁性氧化铁(USPIO)的安全性和潜在的“治疗”效果,以ST抬高型心肌梗死(STEMI)患者进行梗死愈合。最近显示,USPIO给药可改善急性STEMI患者心肌梗死病理的特征。材料和方法17例原发性再灌注STEMI患者(IRON,54±9岁,男性88%)和22名配对对照(CONTROL,57±9岁,男性77%)在第一周和第二周接受了多参数CMR研究。急性心肌梗死后三个月。仅IRON患者在急性MI后四天内接受了510毫克单价铁离子注射剂阿魏酸(FerahemeTM)。结果三个月后,所有患者都还活着,没有出现不良心脏事件。显着改善左室(LV)射血分数(IRON:53±10%至5​​9±9%,p = 0.002; CONTROL:54±6%至57±10%,p = 0.005)以及梗死面积缩小随访时两组均可见。 IRON组梗死面积明显减少(IRON:-10.3±5.4%vs.对照组:-7.0±8.4%,p = 0.050),此外,心内膜范围和跨壁梗死的发生率均显着降低在IRON中但在CONTROL患者中没有左室收缩末期容积仅在IRON组中显着降低(71±25 mL至59±25 mL,p = 0.002)。结论急性STEMI患者静脉输注铁似乎可以改善梗塞愈合和有益的整体左心室重塑。这些发现以及良好的安全性使基于USPIO的铁管理成为急性MI管理中的“诊断”和“治疗”辅助解决方案成为有希望的未来候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号